In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication

Journal of Medical Virology

Volumn 81, Issue 2, 2009, Pages 211-216

  Perez Olmeda, M ^a   Garcia Perez, J ^a   Mateos, E ^a   Spijkers, S ^a   Ayerbe, M C ^b   Carcas, A ^c   Alcami, J ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b Serv Madrileño de Salud Inst de Invest Sanitaria del Hospital Universitario la Paz IdiPaz   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Antagonism; Antiretroviral therapy; HIV; Synergism

Indexed keywords

ABACAVIR; DIDANOSINE; LAMIVUDINE; LUCIFERASE; NUCLEOSIDE; NUCLEOTIDE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; DRUG EFFECT; DRUG INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; VIRUS REPLICATION; CELL CULTURE; CELL LINE; DRUG ANTAGONISM; DRUG POTENTIATION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; VIROLOGY;

ANTI-HIV AGENTS; CELL LINE; CELLS, CULTURED; DRUG ANTAGONISM; DRUG SYNERGISM; HIV INFECTIONS; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 61749096214     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21377     Document Type: Article

References (29)

1. AIDS Study Group (GESIDA) and National AIDS Plan Expert Committee. 2007. Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update January 2007). Enferm Infect Microbiol Clin 25:32-53.
2. Antinori A, Trotta MP, Nasta P, Bini T, Bonora S, Castagna A, Zaccarelli M, Quirino T, Landonio S, Merli S, Tozzi V, Di Perri G, Andreoni M, Perno CF, Carosi G. 2006. Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/ tenofovir in highly active antiretroviral therapy experienced patients. Antivir Ther 11:233-243.
3. Balestre E, Dupon M, Capdepont S, Thiebaut R, Boucher S, Fleury H, Dabis F, Masquelier B, GECSA. 2006. Virological response to HIV-1 nucleoside/ nucleotide reverse transcriptase inhibitors-based, tenofovir DF-including regimens in the ANRS Aquitaine Cohort. J Clin Virol 36:95-99.
4. Barreiro P, Garcia-Benayas T, Rendon A, Rodriguez-Novoa S, Soriano V. 2004. Combinations of nucleoside/nucleotide analogues for HIV therapy. AIDS Rev 6:234-243.
5. Blanco JL, Teniente E, Mallolas J, Martinez E, Lonca M, Laguno M, Larrousse M, Leon A, Milinkovic A, Pumarola T, Gatell JM. 2006. Relation between antirretroviral activity of stavudine (d4T) and the number of reverse transcriptase (RT) mutations: ZENAM study. Antivir Ther 11:S96.
6. Borroto-Esoda K, Vela JE, Myrick F, Ray AS, Miller MD. 2006. In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine. Antivir Ther 11:377-384.
7. Chou TC, Talalay P. 1984. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regu 22:27-55.
8. Connor RI, Chen BK, Choe S, Landau NR. 1995. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 206:935-944.
9. Gallant JE, Rodriguez AE, Weinberg WG, Young B, Berger DS, Lim ML, Liao Q, Ross L, Johnson J, Shaefer MS, ESS30009 Study. 2005. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis 192:1921-1930.
10. Garcia-Perez J, Sanchez-Palomino S, Perez-Olmeda M, Fernandez B, Alcami J. 2007. A new strategy based on recombinant viruses as a tool for assessing drug susceptibility of human immunodeficiency virus type -1. J Med Virol 79:127-137.
11. Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA III, Acosta EP, Schackman BR, Pilcher CD, Murphy RL, Maher WE, Witt MD, Reichman RC, Snyder S, Klingman KL, Kuritzkes DR, AIDS Clinical Trials Group Study A5095 Team. 2004. Triplenucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 Infection. N Engl J Med 350:1850-1861.
12. Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA, International AIDS Society-USA Panel. 2006. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society - USA Panel. JAMA 296:827-843.
13. Hoggard PG, Kewn S, Barry MG, Khoo SH, Back DJ. 1997. Effects of drugs on 2′,3′-dideoxy-2′,3′-didehydrothymidine phosphorylation in vitro. Antimicrob Agents Chemother 41:1231-1236.
14. Holguin A, Ramirez de Arellano E, Rivas P, Soriano V. 2006. Efficacy of antiretroviral therapy in individuals infected with HIV-1 non-B subtypes. AIDS Rev 8:98-107.
15. Jemsek J, Hutcherson P, Harper E. 2004. Poor virologic responses in early emergence of resistance in treatment naive, HIV-infected patients receiving once daily triple nucleoside regimen of didanosine, lamivudine and tenofovir DF, 11th Conference of Retroviruses and Opportunistic Infections, San Francisco, CA. Abstract 51.
16. Khanlou H, Yeh V, Guyer B, Farthing C. 2005. Early virologic failure in a pilot study evaluating the efficacy of therapy containing oncedaily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients. AIDS Patient Care STDS 19:135-140.
17. Landman R, Descamps D, Peytavin G, Trylesinski A, Katlama C, Girard PM, Bonnet B, Yeni P, Bentata M, Michelet C, Benalycherif A, Brun Vezinet F, Miller MD, Flandre P, TONUS (IMEA 021) Study Group. 2005. Early virologic failure and rescue therapy of tenofovir, abacavir, and lamivudine for initial treatment of HIV-1 Infection: TONUS Study. HIV Clin Trials 6:291-301.
18. Louie M, Hogan C, Hurley A, Simon V, Chung C, Padte N, Lamy P, Flaherty J, Coakley D, Di Mascio M, Perelson AS, Markowitz M. 2003. Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals. AIDS 17:1151-1156.
19. Maitland D, Moyle G, Hand J, Mandalia S, Boffito M, Nelson M, Gazzard B. 2005. Early virologic failure in HIV-1 infected subjects on didanosine/ tenofovir/efavirenz: 12-week results from a randomized trial. AIDS 19:1183-1188.
20. Martín-Carbonero L, Gil P, García-Benayas T, Barreiro P, Blanco F, de Mendoza C, Maida I, González-Lahoz J, Soriano V. 2006. Rate of virologic failure and selection of drug resistance mutations using different triple nucleos(t)ide analogue combinations in HIV-infected patients. AIDS Res Hum Retroviruses 22:1231-1235.
21. Merrill DP, Moonis M, Chou TC, Hirsch MS. 1996. Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro. J Infect Dis 173:355-364.
22. Negredo E, Molto J, Burger D, Viciana P, Ribera E, Paredes R, Juan M, Ruiz L, Puig J, Pruvost A, Grassi J, Masmitja E, Clotet B. 2004. Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load. AIDS 18:459-463.
23. Pear WS, Nolan GP, Scott ML, Baltimore D. 1993. Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci 90:8392-8396.
24. Perez-Elias MJ, Moreno S, Gutierrez C, Lopez D, Abraira V, Moreno A, Dronda F, Casado JL, Antela A, Rodriguez MA. 2005. High virological failure rate in HIV patients after switching to a regimen with two nucleoside reverse transcriptase inhibitors plus tenofovir. AIDS 19:695-698.
25. Ray AS, Myrick F, Vela JE, Olson LY, Eisenberg EJ, Borroto-Esodo K, Miller MD, Fridland A. 2005. Lack of a metabolic and antiviral drug interaction between tenofovir, abacavir and lamivudine. Antivir Ther 10:451-457.
26. Rey D, Schmitt MP, Hoizey G, Meyer P, Chavanet P, Allavena C, Diemer M, May T, Hoen B, Lang JM. 2007. Early Virologic Nonresponse to Once Daily Combination of Lamivudine, Tenofovir, and Nevirapine in ART-naive HIV-infected Patients: Preliminary Results of the DAUFIN Study, 14th Conference of Retroviruses and Opportunistic Infections, Los Angeles, CA. Abstract 503.
27. Torti C, Quiros-Roldon E, Regazzi M, Antinori A, Patroni A, Villani P, Tirelli V, Cologni G, Zinzi D, Lo Caputo S, Perini P, Carosi G, KARINA-SISTHER Collaboration Group of the MASTER Cohort. 2005. Early virological failure after tenofovir + didanosine + efavirenz combination in HIV-positive patients upon starting antiretroviral therapy. Antivir Ther 10:505-513.
28. van Leeuwen R, Katlama C, Murphy RL, Squires K, Gatell J, Horban A, Clotet B, Staszewski S, van Eeden A, Clumeck N, Moroni M, Pavia AT, Schmidt RE, Gonzalez-Lahoz J, Montaner J, Antunes F, Gulick R, Banhegyi D, van der Valk M, Reiss P, van Weert L, van Leth F, Johnson VA, Sommadossi JP, Lange JM. 2003. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS 17:987-999.
29. Zhu QY, Scarborough A, Polsky B, Chou TC. 1996. Drug combinations and effect parameters of zidovudine, stavudine, and nevirapine in standardized drug-sensitive and resistant HIV type 1 strains. AIDS Res Hum Retroviruses 12:507-517.